ArticleAnnals of gastroenterological surgery2018
Is high serum programmed death ligand 1 level a risk factor for poor survival in patients with gastric cancer?
Article in Annals of gastroenterological surgery, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
14 citing papers in PubMed.
- Comprehensive Analysis of SIGLEC-15 and PD-L1 Expression Identifies Distinct Prognostic Profiles in Gastric Cancer.International journal of molecular sciences · 2025Article
- Soluble PD-L1: From Immune Evasion to Cancer Therapy.Life (Basel, Switzerland) · 2025Review
- Soluble immune checkpoints: implications for cancer prognosis and response to immune checkpoint therapy and conventional therapies.Journal of experimental & clinical cancer research : CR · 2024Review
- Soluble PD-L1 as a diagnostic and prognostic biomarker in resectable gastric cancer patients.Gastric cancer : official journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association · 2023Article
- Soluble PD‑L1 reflects cachexia status in patients with gastric cancer and is an independent prognostic marker for relapse‑free survival after radical surgery.Molecular and clinical oncology · 2023Article
- Prognostic value of soluble PD-L1 and exosomal PD-L1 in advanced gastric cancer patients receiving systemic chemotherapy.Scientific reports · 2023Article
- The predictive role of soluble programmed death ligand 1 in digestive system cancers.Frontiers in oncology · 2023Review
- Identification of serum anti-striatin 4 antibodies as a common marker for esophageal cancer and other solid cancers.Molecular and clinical oncology · 2021Article
- Soluble PD-L1 is a predictive and prognostic biomarker in advanced cancer patients who receive immune checkpoint blockade treatment.Scientific reports · 2021Article
- Interferon-γ induced PD-L1 expression and soluble PD-L1 production in gastric cancer.Oncology letters · 2020Article
- Programmed death ligand-1 expression in gastrointestinal cancer: Clinical significance and future challenges.Annals of gastroenterological surgery · 2020Review
- The importance of exosomal PDL1 in tumour immune evasion.Nature reviews. Immunology · 2020Review
- High serum PD-L1 level is a poor prognostic biomarker in surgically treated esophageal cancer.Cancer medicine · 2020Observational
- Is high serum programmed death ligand 1 level a risk factor for poor survival in patients with gastric cancer?Annals of gastroenterological surgery · 2018Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
BACKGROUND AND
aimAlthough the clinicopathological significance of the expression of programmed death ligand 1(PD-L1) in various cancer tissues has been reported, serum PD-L1 level has not been evaluated in patients with surgically treated gastric cancer. Therefore, we evaluated the clinicopathological characteristics and prognostic significance of preoperative serum PD-L1 levels in patients with gastric cancer. PATIENTS AND
methodsSerum samples were obtained before surgery from 152 patients with gastric cancer, including 75 patients with stage I, 31 with stage II, 23 with stage III, and 23 with stage IV gastric cancer. The samples were analyzed using enzyme-linked immunosorbent assay to detect soluble PD-L1. Using the median serum PD-L1 level of 50 pg/mL, patients were divided into two groups, namely high serum and low serum PD-L1 level groups. Clinicopathological characteristics and prognosis were compared between these two groups using univariate and multivariate analysis.
resultsSerum PD-L1 level was significantly associated with older age, positive cancer antigen 19-9 (CA19-9), C-reactive protein levels, and albumin levels but not with tumor stage. Patients in the high serum PD-L1 group showed significantly worse overall survival and recurrence-free survival than those in the low serum PD-L1 group (
conclusionHigh serum PD-L1 level was a prognostic factor for reduced overall survival in patients with surgically treated gastric cancer.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.